
Cancer patients in Haiti face death sentence due to distance, gangs, lack of resources
On Saturday, Dieu, known as 'Presnel' to family and friends, lost his years-long battle with cancer. He died in the neighboring Dominican Republic, where he had been receiving radiation treatment with the help of a South Florida-based charity, Flying High 4 Haiti.
'Presnel risked his life just to stay alive,' said Ines Lozano, a Miami resident and founder of Flying High 4 Haiti. 'He clung to hope, attending Mass every Sunday to pray for healing and give thanks to those who supported him. I hope we continue to dream of a future where all cancer patients in Haiti have access to essential treatments like radiotherapy. His legacy lives on through the compassion of all those who donated for his treatment.'
While Dieu, 42, didn't survive his fight, his journey is serving as a stark reminder of the roadblocks and immense challenges Haitians with cancer and other chronic illnesses face amid the country's widespread gang violence and crumbling healthcare infrastructure.
It's also underscoring the need for access to better care. While radiation therapy remans an important part of cancer treatment, there is not a single machine in Haiti, where the last clinic with a gamma radiation device closed more than 20 years ago.
'You should have one radiation machine for every 2 million inhabitants and you have 12 million people in Haiti and we don't even have one machine,' said Dr. Oriol Jn Baptiste, director of the SESHAD Services de Santé Haitiano-Dominicaine, in Santiago de los Caballeros in the northern Dominican Republic, where Dieu was being treated. 'A public health system in charge of a country cannot afford to not be thinking about the treatments for cancer.'
Dieu was 38 and working at a school Flying High 4 Haiti supports in Ille-a-Vache, an island off Haiti's southwestern coast, when he first discovered he had a tumor.
In the last few months, Haitians have not only seen the further collapse of their already fragile healthcare system, but for those with cancer, life-saving treatment has become even harder to obtain.
In March, gangs attacked the city of Mirebalais, forcing the evacuation of the 35-bed University Hospital of Mirebalais. Haiti's most modern health facility, the hospital offered free cancer care and was featured in the Miami Herald's 2019 series 'Cancer in Haiti.' The series explored how deaths from preventable diseases like cervical cancer were growing due to limited early detection programs and a lack of radiation treatment. The series also explored the lack of public health priority to pediatric cancer cases.
The attack on Mirebalais was among several on hospitals that has stopped 40% of health facilities in the capital from operating. Among them is the St. Francis de Sales Hospital, which treated hundreds of cancer patients annually.
'It has been very rough,' said Dr. Joseph Bernard, an oncologist who worked at the Catholic hospital and has since opened his own private cancer clinic, Clinique de Cancer St Francois de Sales, in the capital. Dr. Bernard was Dieu's doctor before he was forced to seek care in the Dominican Republic because the chemotherapy had run its course.
Dr. Bernard said since the closure of Mirebalais and St. Francis, demand for care has gone up and many patients are at advanced stages. of the disease.
In addition to having to pay for previously free care, patients from Mirebalais face another complication: The cancer specialist hasn't been able to get access to their charts. Then, there is the lack of treatment equipment.
'We still have limitations regarding radiation therapy,' Dr. Bernard said.
In the past, patients had the possibility of traveling to the Dominican Republic or Cuba if they had the financial means. However both have become nearly impossible to get to because of medication shortages and a lack of direct flights in the case of Cuba, and border closures with the Dominican Republic.
As a result, patients, including children in need of radiation therapy, have had difficulties getting humanitarian visas to seek treatment.
'I've been fighting for two years for a humanitarian visas for Haitians who need treatment; I've written to the Dominican consulate and they never answered me,' said Dr. Baptiste, who added he was working with Nos Petits Frères et Sœurs in Port-au-Prince, which offers the only juvenile cancer program in Haiti, to transfer cases to the Dominican Republic for radiation treatment before the border closed.
In 2021, Dieu spent six months undergoing radiotherapy in the Dominican Republic for his cancer. He was doing well until a small tumor was detected behind the right ear, Dr. Bernard said. 'We tried to shrink it with chemo. It did not work. The tumor started to bleed a lot and it became very infected.'
'When cancer reoccurs, it's very aggressive,' said Dr. Bernard, noting that radiotherapy is one of the three main components of cancer care, which also includes surgery as well as chemo. 'In the end, he needed radiation therapy.'
During a visit to the Dominican Republic, Lozano, who had arranged for Dieu's prior treatment with the help of Nuestros Pequeños Hermanos, a Catholic children's charity with programs in Latin America and the Caribbean, approached officials about getting a humanitarian visa for Dieu and his wife. It came a few weeks later. With Dieu too weak to make the journey by road, Lozanao arranged for him to fly from Les Cayes to Cap-Haïtien, the country's second largest city in the north. He then traveled to the border, where an ambulance transported him to the clinic in Santiago, three hours away.
Radiation treatment is expensive and most of the patients never finish the course, said Baptiste, who noted that the stay in the Dominican Republic also adds up the costs. He determined that Dieu would need at least 33 rounds of radiotherapy over 10 weeks. The cost was $19,000, which Lozano had hoped to absorb with the help of a GoFundme effort that remains open.
On Saturday, Dieu collapsed. It's unclear what went wrong, though he arrived for treatment needing six rounds of blood transfusions with his head severely infected.
Dr. Bernard said most people don't realize the psychological toll Haiti's present gang crisis poses for cancer patients.
'There are a lot of things we really cannot evaluate, like the impact of stress, for example, on treatment outcomes' he said. 'These are things that are tough to evaluate but we need to consider them seriously.'
In the case of Dieu, he faced a perilous journey trying to get to treatment in Haiti before he went to the Dominican Republic. What previously consisted of a boat ride from Ille-a-Vache and then a bus ride into the capital along a main highway suddenly became an arduous journey through gang tolls, shootouts and police blockades.
After temporarily moving to Port-au-Prince to get to his treatments he sent a voice message one day, over the sound of gunfire, explaining that he could not get there because the capital had become a war zone.
Lozano began to fear that if the cancer didn't kill Dieu the gangs would. She hired a driver to transport him overnight on the back of a motorbike. He made the seven-hour journey every 21 days to get to his chemo treatments.
When traveling 5,000 feet high along a mountain range, no longer became an option this year after gangs seized control of the last open road in the hills above the capital in Kenscoff, Dieu, with his head wrapped in bandages, texted to say that he had found another way: via barge through the bay of Port-au-Prince.
Dr. Bernard will be expanding his services next month to Les Cayes at the private Caramel Hospital. It will be the first oncology unit in the coastal southwestern city where many cancer patients from the south are diagnosed too late or not at all.
'Too many Haitian women are dying from cancers that are treatable, simply because there is no access to care in the south,' said Skyler Badenoch, who runs Hope for Haiti, a Naples-based nonprofit that provides health care access in southwest Haiti. 'Dr. Bernard's plan to open a cancer treatment facility in this region could be transformational. Together, we can bring early detection, treatment and dignity within reach, and ensure that where someone lives no longer determines whether they live.'
Lozano says the expansion of cancer care to the south is good news.
'There are a large number of patients in the south who haven't been able to go chemo or anything, and they're dying,' she said, adding that Bernard's clinic opening will bring a lot of hope. 'In spite of all the problems that exist in Haiti, there's a lot of acts of hope that people don't know.'
On Sunday, an ambulance, paid for by Lozano, transported Dieu's body in a casket back across the Haitian-Dominican border so. his four children could say goodbye.
'We had high hopes for a better outcome, but at least he died with dignity and receiving the kind of care every Haitian deserves,' said Lozano. 'That is his legacy. I hope that Presnel's battle serves as an example of the urgent need for radiotherapy in Haiti to save other lives.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Press Release: Sanofi's SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma
Sanofi's SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment of patients with relapsed or refractory multiple myeloma Paris, July 30, 2025. The US Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, an IgG1-based Antibody-Dependent Cellular Cytotoxicity-enhanced (ADCC) monoclonal antibody (mAb) targeting G-protein coupled receptor family C group 5 member D (GPRC5D) for the potential treatment of patients with relapsed or refractory multiple myeloma (R/R MM). GPRC5D is highly expressed on plasma cells in MM patients, with low expression in healthy tissues. The FDA grants orphan drug designation to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the US. 'The orphan drug designation is a significant milestone in our ongoing efforts to develop innovative treatments in multiple myeloma,' said , Global Therapeutic Area Head, Immunology and Oncology Development at Sanofi. 'This underscores our commitment to multiple myeloma, a disease for which we have acquired strong expertise with the development of another widely used and approved immunotherapy treatment.' The safety and efficacy of SAR446523 has not been evaluated by any regulatory authority and is still under investigation. About SAR446523SAR446523 is an investigational IgG1-based mAb designed to target GPRC5D, which is highly expressed on plasma cells, with an engineered fragment crystallizable domain to enhance antibody dependent cell-mediated cytotoxicity. This innovative approach aims to improve the efficacy of treatment for MM, a rare and challenging cancer of plasma cells. Subcutaneous SAR446523 is currently being evaluated in an ongoing phase 1, first-in-human study in patients with R/R MM (clinical study identifier: NCT06630806). SAR4465523 originates from Sanofi Research in Vitry-sur-Seine, France. About multiple myelomaMultiple myeloma is considered a rare disease, yet MM is the second most common hematologic malignancy with more than 180,000 people diagnosed with MM each year, globally. Despite available treatments, MM remains an incurable malignancy with an estimated 62% five-year survival rate for newly diagnosed patients. There is a need for new frontline therapeutic options for all patients, especially for those who are transplant ineligible, due to high attrition rates in subsequent lines of therapy. Since MM does not have a cure, most patients will relapse and stop responding to therapies they have received. At Sanofi, we are building on a long-standing commitment to oncology as we continue to chase the miracles of science to improve the lives of those living with cancer. We are committed to transforming cancer care by developing innovative, first and best-in-class immunological and targeted therapies for rare and difficult-to-treat cancers with high unmet need. For more information on MM clinical studies, please visit About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | Berland | +1 215 432 0234 | Léo Le Bourhis | +33 6 75 06 43 81 | Victor Rouault | +33 6 70 93 71 40 | Timothy Gilbert | +1 516 521 2929 | Ubaldi | +33 6 30 19 66 46 | Investor RelationsThomas Kudsk Larsen |+44 7545 513 693 | Alizé Kaisserian | +33 6 47 04 12 11 | Lauscher | +1 908 612 7239 | Keita Browne | +1 781 249 1766 | Pham | +33 7 85 93 30 17 | Elgoutni | +1 617 710 3587 | Thibaud Châtelet | +33 6 80 80 89 90 | Yun Li | +33 6 84 00 90 72 | Sanofi forward-looking statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi Press Release
Yahoo
an hour ago
- Yahoo
Press Release: Sanofi's SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma
Sanofi's SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment of patients with relapsed or refractory multiple myeloma Paris, July 30, 2025. The US Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, an IgG1-based Antibody-Dependent Cellular Cytotoxicity-enhanced (ADCC) monoclonal antibody (mAb) targeting G-protein coupled receptor family C group 5 member D (GPRC5D) for the potential treatment of patients with relapsed or refractory multiple myeloma (R/R MM). GPRC5D is highly expressed on plasma cells in MM patients, with low expression in healthy tissues. The FDA grants orphan drug designation to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the US. 'The orphan drug designation is a significant milestone in our ongoing efforts to develop innovative treatments in multiple myeloma,' said , Global Therapeutic Area Head, Immunology and Oncology Development at Sanofi. 'This underscores our commitment to multiple myeloma, a disease for which we have acquired strong expertise with the development of another widely used and approved immunotherapy treatment.' The safety and efficacy of SAR446523 has not been evaluated by any regulatory authority and is still under investigation. About SAR446523SAR446523 is an investigational IgG1-based mAb designed to target GPRC5D, which is highly expressed on plasma cells, with an engineered fragment crystallizable domain to enhance antibody dependent cell-mediated cytotoxicity. This innovative approach aims to improve the efficacy of treatment for MM, a rare and challenging cancer of plasma cells. Subcutaneous SAR446523 is currently being evaluated in an ongoing phase 1, first-in-human study in patients with R/R MM (clinical study identifier: NCT06630806). SAR4465523 originates from Sanofi Research in Vitry-sur-Seine, France. About multiple myelomaMultiple myeloma is considered a rare disease, yet MM is the second most common hematologic malignancy with more than 180,000 people diagnosed with MM each year, globally. Despite available treatments, MM remains an incurable malignancy with an estimated 62% five-year survival rate for newly diagnosed patients. There is a need for new frontline therapeutic options for all patients, especially for those who are transplant ineligible, due to high attrition rates in subsequent lines of therapy. Since MM does not have a cure, most patients will relapse and stop responding to therapies they have received. At Sanofi, we are building on a long-standing commitment to oncology as we continue to chase the miracles of science to improve the lives of those living with cancer. We are committed to transforming cancer care by developing innovative, first and best-in-class immunological and targeted therapies for rare and difficult-to-treat cancers with high unmet need. For more information on MM clinical studies, please visit About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | Berland | +1 215 432 0234 | Léo Le Bourhis | +33 6 75 06 43 81 | Victor Rouault | +33 6 70 93 71 40 | Timothy Gilbert | +1 516 521 2929 | Ubaldi | +33 6 30 19 66 46 | Investor RelationsThomas Kudsk Larsen |+44 7545 513 693 | Alizé Kaisserian | +33 6 47 04 12 11 | Lauscher | +1 908 612 7239 | Keita Browne | +1 781 249 1766 | Pham | +33 7 85 93 30 17 | Elgoutni | +1 617 710 3587 | Thibaud Châtelet | +33 6 80 80 89 90 | Yun Li | +33 6 84 00 90 72 | Sanofi forward-looking statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi Press Release


Miami Herald
7 hours ago
- Miami Herald
David Nabarro, doctor who tried to raise millions to treat cholera in Haiti, dies at 75
The United Nations and world health community are mourning the death of David Nabarro, the British physician and public health champion who led the U.N response to eradicating cholera in Haiti after taking on some of the world's most pressing diseases, including Ebola. A passionate advocate who was once described to the Miami Herald as the U.N.'s go-to guy for responding 'to really tricky' situations, Nabarro died Friday at his home in Ferney-Voltaire, France, a suburb of Geneva, according to the 4SD Foundation, a Switzerland-based social enterprise he founded and where he served as strategic director. He was 75. His passing was described as a 'sudden death.' 'Dr. Nabarro was a tireless advocate for global health -- a leader who brought clarity, compassion and conviction to some of the world's most complex health emergencies, from AIDS and malaria to avian influenza and the COVID-19 pandemic,' Farhan Haq, deputy spokesperson for U.N. Secretary-General António Guterres, said in a statement Tuesday. 'He dedicated his life to the conviction that health is a human right — and worked to help make that right a reality for all people everywhere,' Haq added. Nabarro was known for his organized, results-oriented style and willingness to take personal risks. During the COVID pandemic, he served as one of six special envoys to the World Health Organization dealing with the coronavirus crisis. For his efforts and overall contributions to global health, he was knighted by King Charles III in 2023. Among those contributions was his fight against Ebola. With more than 30 years experience as a public health doctor when he was appointed coordinator of the U.N's efforts, Nabarro ended up raising $3.5 billion to fight Ebola despite the incessant and worrying questions from donors asking him if he knew what he was doing and if he had a strategy. 'There was a question mark always over whether or not we had a strategy that made sense, whether or not we knew what we were up to,'' he told the Herald in a 2016 interview. Soon he faced the same kinds of question as he tried to raise $400 million for the U.N.'s cholera plan in Haiti. Nabarro had been tapped to serve as special adviser to then Secretary-General Ban Ki-moon, who after years of fighting litigation efforts by victims and refusing to acknowledge the U.N.'s role in inadvertently introducing the deadly disease into Haiti, was ready to take it on the problem. Scientific studies and a confidential U.N. report had traced Haiti's outbreak to Nepalese soldiers, part of a U.N. peacekeeping contingent stationed near a river in the rural town of Mirebalais after the devastating Jan. 12, 2010, earthquake. By the time Nabarro was involved cholera had killed at least 9,393 people and sickened more than 790,840 in the Caribbean country. His job was to help the secretary general raise hundreds of millions of dollars over two years to fund a U.N. plan to eliminate cholera with rapid responses, vaccinations and improving long-term access to clean water and sanitation. By the time Nabarro came on the scene in late 2016, Ban had finally admitted the U.N.'s role and offered an apology during a meeting of the U.N. General Assembly. He wanted Nabarro to do for cholera what he had done for Ebola in Africa: galvanize government efforts and raise money. 'I have no illusions about this. It's going to be tough,' Nabarro told the Herald two weeks before visiting Haiti with Ban. 'But I am not scared by it.' Over the next few months, Nabarro made other visits and devoted himself to the cholera problem as well as to the fight against global hunger. To understand the waterborne disease's evolution and response, he reached out to a number of public health experts including Ariel Henry. The physician, who would later serve as Haiti's prime minister, was in the administration of then-President René Préval and was helping with the government's response. At the time Préval was facing immense pressure from the Obama administration to hold presidential and legislative elections in Haiti despite the deaths of more than 300,000 people and 1.5 million homeless in the quake. Fearing that placing blame on the U.N. would lead to the departure of its blue helmet peacekeepers and open the door to more violence and instability, Préval tried to manage the response on his own. But as time went by, pressure built for the U.N. to not only acknowledge its role but to apologize and compensate victims. Instead of checks to victims, Ban called for vaccinating adults and dispatching more rapid response teams within 24 to 48 hours of an infection. He also pledged that the U.N. would improve water and sanitation in places where cholera had spread. In an email exchange in 2017 while vying for the top job at the World Health Organization, Nabarro acknowledged that the effort to raise financing to eradicate cholera in Haiti had not been easy. The amount of money raised was small, but he still held onto hope that the benefits would be enormous. 'I really do hope that I get to the director general of the World Health Organization as I would then be able to give a very high priority to a concerted and sustained effort to reduce the incidence of cholera in the country and to help all Haitians to access drinking water and functioning sanitation,' he told a Herald reporter. Nabarro lost out on the WHO job to Tedros Adhanom Ghebreyesus. In a post on the social media platform X on Saturday, Ghebreyesus remembered Nabarro as 'a great champion of global health and health equity, and a wise, generous mentor to countless individuals.' Through Nabarro's efforts and those of others in Haiti, the country was declared cholera-free in February 2022 by Henry, now the country's prime minister, after three years without a confirmed case. The celebration was short-lived. By the end of the year, repeated gang clashes, which cut off access to water, fuel and hospitals in Port-au-Prince, gave rise to a resurgence of cholera cases. Nabarro is survived by his wife, Flo; his children, Tom, Ollie, Polly, Josie and Lucas, and seven grandchildren.